Therapies with systemic (oral and intravenous) corticosteroids and their alteration due to the COVID-19 pandemic
| Intravenous corticosteroids | |
| Number of patients who received intravenous corticosteroids | 11 |
| Number of patients who required but did not receive intravenous corticosteroids* | 7 |
| Oral corticosteroids | |
| Total number of patients on oral corticosteroids during the study period (out of 176 patients) | 94 (53.4%) |
| Number of patients on oral corticosteroids in maintenance phase† | 33 (35.1%) |
| Number of patients initiated on oral corticosteroids for active uveitis‡ | 61 (64.9%) |
| Number of patients who were initiated on oral corticosteroids for active uveitis, and received rapid tapering regimen (>10 mg/week reduction in dose) | 35 (57.4%) |
| Number of patients who required oral corticosteroids for active uveitis but did not receive§ | 20 (22.2%) |
| Number of patients who stopped corticosteroids on their own | 8 |
*Indicates patients who required intravenous corticosteroids for severe uveitis as deemed by the treating ophthalmologist.
†Indicates those patients who were already on a stable dose of ≤10 mg/kg/day oral prednisolone at the beginning of the study since their uveitis was deemed to be quiescent/inactive.
‡Indicates the number of patients who were initiated on high-dose oral corticosteroids for active uveitis (1 mg/kg/day oral prednisolone).
§Indicates patients who required oral corticosteroids for active uveitis as deemed by the treating ophthalmologist, but were treated with other agents such as intravitreal therapies.